Assessment of influence on plasma eicosapentanoic acid(EPA) /arachidonic acid(AA) ratio of highly purified eicosapentanoic acid

Assessment of influence on plasma eicosapentanoic acid(EPA) /arachidonic acid(AA) ratio of highly purified eicosapentanoic acid - Assessment of influence on plasma EPA/AA ratio of highly purified EPA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002942

Enrollment

100

Registered

2009-12-25

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart disease patients who have dyslipidemia

Interventions

Take EPA 600mg after every meal 3 times a day (1800mg/day) for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ischemic heart disease patients with dyslipidemia

Exclusion criteria

Exclusion criteria: nondyslipidemia patients

Design outcomes

Primary

Measure	Time frame
Effectiveness to plasma EPA/AA ratio will be evaluated before it takes highly purified EPA and after six months in ischemic heart disease patients who have dyslipidemia	—

Secondary

Measure	Time frame
Plasma EPA/AA ratio of ischemic heart disease patients who have dyslipidemia	—

Countries

Japan

Contacts

Public ContactMasatake Sato

Shimane University Faculty of Medicine Division of Cardiology

0853-20-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026